ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Herceptin Recommended As Adjuvant For HER2 Positive Early Breast Cancer

May 27, 2005

In Brief: Evaluation Of Potential Immunoassay Components Sought; Promising Results Could Lead to Contract

September 19, 1975

Hong Succeeds Curran As AACR President, Horwitz Is President-Elect; 5 New Directors.

March 30, 2001

Panel To Take Up Issues In Grant/Peer Review System, Consider NCAB Membership Requirements

December 11, 1981

Upton Briefed On Problems; To Start July 25

July 15, 1977

White House Picks Harold Varmus For NCI

May 21, 2010